SRRK Quote, Financials, Valuation and Earnings

Altimmune has a net margin of -- compared to Scholar Rock Holding's net margin of -463600%. Scholar Rock Holding's return on equity of -- beat Altimmune's return on equity of -61.21%.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 59.61%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 361.34%. Given that Altimmune has higher upside potential than Scholar Rock Holding, analysts believe Altimmune is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Altimmune has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.323%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Altimmune quarterly revenues of $5K. Scholar Rock Holding's net income of -$66.5M is lower than Altimmune's net income of -$23.2M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 66.78x versus 17,220.09x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Scholar Rock Holding's net margin of 32.59%. Scholar Rock Holding's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 59.61%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 21.88%. Given that Scholar Rock Holding has higher upside potential than Eli Lilly and, analysts believe Scholar Rock Holding is more attractive than Eli Lilly and.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Scholar Rock Holding quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Scholar Rock Holding's net income of -$66.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 70.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 66.78x versus 16.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of 24.22%. Scholar Rock Holding's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 59.61%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $871.30 which suggests that it could grow by 48.82%. Given that Scholar Rock Holding has higher upside potential than Regeneron Pharmaceuticals, analysts believe Scholar Rock Holding is more attractive than Regeneron Pharmaceuticals.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Scholar Rock Holding's net income of -$66.5M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 66.78x versus 4.74x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Viking Therapeutics's return on equity of --.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 59.61%. On the other hand Viking Therapeutics has an analysts' consensus of $91.89 which suggests that it could grow by 260.63%. Given that Viking Therapeutics has higher upside potential than Scholar Rock Holding, analysts believe Viking Therapeutics is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Scholar Rock Holding's net income of -$66.5M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 66.78x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.